Affiliation:
1. Instituto de Química Rosario (IQUIR‐CONICET) Rosario Argentina
2. NEUROFARBA Department, Pharmaceutical Chemistry Section University of Florence Florence Italy
3. National Center for Natural Products Research & Department of Pharmacology, School of Pharmacy University of Mississippi University Mississippi USA
4. Laboratorio de Microbiología Molecular, Facultad de Ciencias Médicas Universidad Nacional de Rosario Rosario Santa Fe Argentina
5. Consejo de Investigaciones Universidad Nacional de Rosario Rosario Argentina
6. Departamento de Química Orgánica, Facultad de Ciencias Bioquímicas y Farmacéuticas Universidad Nacional de Rosario Rosario Argentina
Abstract
AbstractIn previous studies, we demonstrated the potent activity of a library of 25 N,N′‐disubstituted diamines (NNDDA) toward Trypanosomatid and Apicomplexa parasites. Considering the structure similarity between this collection and SQ109, an antituberculosis compound, and its compelling antiparasitic properties, we aimed to repurpose this library for tuberculosis treatment. We assayed this collection against Mycobacterium tuberculosis H37Rv and M. avium, obtaining several compounds with MIC values below 10 µM. The most active analogs were also evaluated against M. smegmatis, a non‐pathogenic species, and the non‐tuberculosis mycobacteria M. abscessus, M. kansasii, and M. fortuitum. 3c stands out as the lead mycobacterial compound of the collection, with potent activity against M. tuberculosis (minimal inhibitory concentration [MIC] = 3.4 µM) and moderate activity against M. smegmatis, M. kansasii, and M. fortuitum (all with MIC values of 26.8 µM). To unravel the mechanism of action, we employed the web‐based platform Polypharmacology Browser 2 (PPB2), obtaining carbonic anhydrases as potential drug targets. Nevertheless, none of the compounds displayed experimental inhibition. In summary, our study confirms the validity of the repurposing approach and underscores the antimycobacterial potential of NNDDA compounds, especially the analog 3c, setting a stepping stone for further studies.
Reference41 articles.
1. World Health Organization (WHO) https://www.who.int/news-room/fact-sheets/detail/tuberculosis(accessed: May 2024) (n.d.).
2. World Health Organization (WHO) The End TB Strategy 2014.
3. World Health Organization (WHO) Global tuberculosis report 2023 2023.
4. World Health Organization (WHO) https://www.who.int/news/item/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis(accessed: May 2024) (n.d.).
5. The mycobacterial cell wall